Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)
Misako Nagasaka(University of California, Irvine), Asfar S. Azmi(The Barbara Ann Karmanos Cancer Institute), Hossein Borghaei(Fox Chase Cancer Center), Luis E. Raez(Florida International University), Hirva Mamdani(Wayne State University), W. Michael Korn(Itasca Community College), Mohammad Asad(Wayne State University), Stephen V. Liu(Georgetown University), Mohammed Najeeb Al Hallak(The Barbara Ann Karmanos Cancer Institute), C. Patrick(Penn State Milton S. Hershey Medical Center), Sonam Puri(University of Utah), Md. Hafiz Uddin(Wayne State University), Gilberto Lopes(University of Miami), Jorge J. Nieva(University of Southern California), Yasmine Baca(Caris Life Sciences (United States)), Michael J. Demeure(Hoag Memorial Hospital Presbyterian), Joanne Xiu(Caris Life Sciences (United States)), Dipesh Uprety(The Barbara Ann Karmanos Cancer Institute), Dan Magee(Caris Life Sciences (United States)), Bing Xia(Rutgers, The State University of New Jersey), Gerold Bepler(Moffitt Cancer Center), Chul Kim(Georgetown University), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute)
Cited by 15
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k